Test Price
2,800 AED✅ Home Collection Available
AMH Gene Persistent Müllerian Duct Syndrome Type 1 Genetic Test in UAE | AED 2,800
Executive Summary & Core Metrics
Guarantee: 99.9% diagnostic sensitivity via ISO-certified NGS processing. Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection, available daily from 8 AM to 11 PM. Clinical Support: Telephonic post-test clinical guidance for result interpretation by a consultant medical geneticist. Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The AMH gene Next-Generation Sequencing (NGS) test detects pathogenic variants in the anti-Müllerian hormone gene responsible for Persistent Müllerian Duct Syndrome Type 1, a rare 46,XY disorder of sexual development where genetic males retain female internal reproductive structures. This analysis is crucial for confirming diagnosis, guiding fertility preservation strategies, and enabling informed family planning.
| Feature | Our Test (NGS Sequencing) | Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% sensitivity, full gene coverage | ~95% sensitivity, limited to known hotspots |
| Methodology | Next-Generation Sequencing (NGS) | Sanger Sequencing (individual exons) |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
Physician Insight & Safety Protocols
"As a consultant medical geneticist, I want to assure you that a positive AMH variant result is only one piece of the diagnostic picture. It must be correlated with clinical findings and family history to guide meaningful decisions regarding fertility preservation and surgical management. We are committed to walking this path with evidence-based compassion."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Pre-Test Advisory
Do not alter or discontinue any prescribed medications without consulting your treating physician. Genetic testing provides diagnostic information and does not replace current treatment plans. Always discuss result implications with your healthcare provider before making clinical decisions.
Exclusion Criteria & Urgent Red Flags
- Not suitable for individuals who received a blood transfusion within the last 2 weeks.
- Patients on DNA-damaging chemotherapy should postpone testing unless cleared by their oncologist.
- If the patient is a minor, written informed consent from a legal guardian is mandatory in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
ER Red Flag: Sudden severe abdominal or groin pain in a patient with suspected PMDS could indicate testicular torsion or incarcerated hernia – seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What does this test detect?
This NGS test sequences the AMH gene to detect pathogenic mutations causing Persistent Müllerian Duct Syndrome Type 1, a rare 46,XY disorder of sexual development characterized by retained Müllerian structures (uterus, fallopian tubes, upper vagina) in phenotypically male individuals.
2. Who should consider this test?
Individuals with ambiguous genitalia, cryptorchidism (undescended testes), inguinal hernias containing Müllerian structures, or a family history of PMDS should consider this test for definitive diagnosis and genetic counseling.
3. How accurate is the test?
With a sensitivity of 99.9%, our NGS-based analysis provides near-definitive detection of AMH gene mutations, covering the entire coding region and splice sites. Confirmatory Sanger sequencing is performed on all clinically significant findings.
4. What sample is required and how is it collected?
A standard peripheral whole blood sample (3–5 mL in EDTA tube) is required. VIP mobile phlebotomy for home collection is available daily from 8 AM to 11 PM via temperature-controlled cold-chain courier.
5. How long does it take to get results?
The standard turnaround time is 3–4 weeks from sample receipt at our laboratory. Expedited processing may be available upon request for urgent clinical cases.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority (DHA) with full adherence to UAE federal laws governing health data protection:
- Data Privacy: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing all patient information processing, storage, and sharing.
- Health Information Technology: Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating electronic health records and telemedicine practices.
- Clinical Safety: Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring informed consent protocols and patient safety standards.
All genetic data is encrypted at rest and in transit, with access restricted to authorized clinical personnel only. Results are securely transmitted via HIPAA-compliant channels.
Clinical & Logistical Metadata
| Test Name | AMH Gene Persistent Müllerian Duct Syndrome Type 1 Genetic Test |
| Price (AED) | AED 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood — VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) — Full Gene Coverage including coding exons and splice sites |
| ICD-10-CM Code | Q55.8 |
| LOINC Code | 81653-4 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians